(Q38062861)

28 August 2017

1 reference

title

Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). (English)

1 reference

28 August 2017

0 references

Andrew D Goodman

1

1 reference

28 August 2017

Robert Thompson Stone

series ordinal

2

1 reference

28 August 2017

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

10

1 reference

28 August 2017

1

1 reference

28 August 2017

106-110

1 reference

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials

28 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Contribution of impaired mobility to patient burden in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Sustained-release fampridine for symptomatic treatment of multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Voltage-gated potassium channels are required for human T lymphocyte activation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Mitogen induction of ion channels in murine T lymphocytes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Repetitive action potentials in isolated nerve terminals in the presence of 4-aminopyridine: effects on cytosolic free Ca2+ and glutamate release

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Single-Dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Dose comparison trial of sustained-release fampridine in multiple sclerosis

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Intravenous infusion of 4-AP in chronic spinal cord injured subjects.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3557354

Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension

31 August 2018

1 reference

12 December 2020

Seizures in multiple sclerosis

1 reference

12 December 2020

Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation

1 reference

12 December 2020

Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission

1 reference

12 December 2020

Effects of 4-aminopyridine in patients with multiple sclerosis

1 reference

12 December 2020

Effects of 4-Aminopyridine in Elderly Patients with Alzheimer’s Disease

1 reference

12 December 2020

4-Aminopyridine in multiple sclerosis: prolonged administration

1 reference

12 December 2020

The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study

1 reference

12 December 2020

Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury

1 reference

12 December 2020

4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients

1 reference

12 December 2020

4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety

1 reference

12 December 2020

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

1 reference

12 December 2020

Gait and balance impairment in early multiple sclerosis in the absence of clinical disability

1 reference

12 December 2020

10.1007/S13311-012-0156-3

Identifiers

DOI

1 reference

release_fply7jpusfdojfjhusxr3tmmx4

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fply7jpusfdojfjhusxr3tmmx4

24 November 2022

mapped directly with Wikidata item

1 reference

28 August 2017

PubMed publication ID

23184313

1 reference